Skip to main content
|
  1. Home
  2. Clinical Trials
  3. NRG-LU007/RAPTOR

Addition of Radiation Therapy to Immune Therapy for Extensive Stage Small Cell Lung Cancer

Short Title: NRG-LU007/RAPTOR


Enrollment Status: Recruiting

NCT #: NCT04402788

Specialty Area: Oncology

Condition Studied: Extensive Stage Small Cell Lung Cancer

Age Groups: Adult; Older Adult

Phase: II/III


Study Information

Summary / Purpose

To find out if adding radiation therapy to atezolizumab helps people with extensive stage small cell lung cancer live longer or stay free from cancer growth longer than atezolizumab alone.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (cancer that has spread beyond the lungs)
  • Must have already received atezolizumab plus chemotherapy
  • Must be eligible to continue maintenance therapy

What's Involved

Participation in the study will include:
  • Treatment with atezolizumab given intravenously (IV) with or without radiation therapy
  • CT scans, MRI, and PET scans to monitor response to treatment
  • Blood and tissue sample collection to monitor your health and treatment effects
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT04402788

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up